Fate Therapeutics, Inc. (FATE)
Automate Your Wheel Strategy on FATE
With Tiblio's Option Bot, you can configure your own wheel strategy including FATE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FATE
- Rev/Share 0.1126
- Book/Share 2.4364
- PB 0.5418
- Debt/Equity 0.2889
- CurrentRatio 8.8148
- ROIC -0.5173
- MktCap 151315560.0
- FreeCF/Share -1.0574
- PFCF -1.2089
- PE -0.8884
- Debt/Assets 0.209
- DivYield 0
- ROE -0.5149
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment.
Read More
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
Read More
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications
Read More
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
Read More
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Fate Therapeutics to Present at Upcoming Investor Conferences
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:
Read More
About Fate Therapeutics, Inc. (FATE)
- IPO Date 2013-10-01
- Website https://www.fatetherapeutics.com
- Industry Biotechnology
- CEO Dr. Bahram Valamehr M.B.A., Ph.D.
- Employees 181